| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1176/AJP.150.5.695 |
| P698 | PubMed publication ID | 8097618 |
| P50 | author | Marc A. Schuckit | Q42577979 |
| Marian Fischman | Q69415887 | ||
| P2093 | author name string | Kosten TR | |
| Satel SL | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 695-704 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Should protracted withdrawal from drugs be included in DSM-IV? | |
| P478 | volume | 150 |
| Q34417561 | A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence |
| Q36216488 | Aggressive behavior among military veterans in substance use disorder treatment: the roles of posttraumatic stress and impulsivity |
| Q28360988 | Alcohol's effects on sleep in alcoholics |
| Q51873685 | Alexithymia and personality dimensions in relation to depression and anxiety in male alcohol-dependent inpatients. |
| Q24241305 | Alpha 2 -adrenergic agonists for the management of opioid withdrawal |
| Q24185795 | Alpha2-adrenergic agonists for the management of opioid withdrawal |
| Q24197769 | Alpha2-adrenergic agonists for the management of opioid withdrawal |
| Q38950890 | Buprenorphine for managing opioid withdrawal |
| Q24240149 | Buprenorphine for the management of opioid withdrawal |
| Q34631150 | Cerebral metabolism and mood in remitted opiate dependence |
| Q36575862 | Comorbidity of substance use with depression and other mental disorders: from Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) to DSM-V. |
| Q34555005 | Complications of alcohol withdrawal: pathophysiological insights. |
| Q33988978 | Craving among long-abstinent smokers: an Internet survey |
| Q99585315 | Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development |
| Q35934883 | Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol |
| Q43619996 | Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers |
| Q43432977 | Effects of haloperidol in a response-reinstatement model of heroin relapse |
| Q34444149 | Evidence-based addiction medicine: the use of lofexidine for opioid detoxification. |
| Q33938089 | Impact of substance abuse on the course and treatment of bipolar disorder |
| Q41191250 | Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal |
| Q38600584 | Increased habenular connectivity in opioid users is associated with an α5 subunit nicotinic receptor genetic variant. |
| Q28354377 | Insomnia, self-medication, and relapse to alcoholism |
| Q24598228 | Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety? |
| Q36853330 | Motivational Processes Underlying Substance Abuse Disorder |
| Q24681779 | Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment |
| Q40582981 | Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities |
| Q24240954 | Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal |
| Q24246081 | Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal |
| Q34202486 | Opioid antagonists under sedation or anaesthesia for opioid withdrawal |
| Q24240041 | Opioid antagonists with minimal sedation for opioid withdrawal |
| Q24244653 | Opioid antagonists with minimal sedation for opioid withdrawal |
| Q56289303 | Opioid antagonists with minimal sedation for opioid withdrawal |
| Q36123234 | Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates |
| Q40576026 | Predicting completion of outpatient opioid detoxification with clonidine |
| Q30440436 | Protracted manifestations of acute dependence after a single morphine exposure |
| Q51621560 | Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. |
| Q39670912 | Relationship between platelet serotonin uptake sites and measures of impulsivity, aggression, and craving among African-American cocaine abusers |
| Q37415518 | Risk of Hospital Readmission Among Infants With Neonatal Abstinence Syndrome |
| Q36939580 | Serum cortisol secretion during heroin abstinence is elevated only nocturnally |
| Q40582992 | Stimulant withdrawal |
| Q41678771 | The apomorphine test in heroin addicts |
| Q41996190 | The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary |
| Q46953419 | The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects |
| Q44977940 | The importance of sleep for healthy alcohol consumers and alcohol dependent patients |
| Q55887262 | The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls |
| Q41127953 | The management of treatment resistance in depressed patients with substance use disorders |
| Q44070882 | The use of divalproex in alcohol relapse prevention: a pilot study |
| Q43842919 | Trauma and substance cue reactivity in individuals with comorbid posttraumatic stress disorder and cocaine or alcohol dependence |
| Q33883673 | Vaccines for cocaine abuse |
| Q43960579 | Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients |
Search more.